Exploiting the understanding of the interdependencies between ovarian cancer cells and the microenvironment requires the discovery of therapeutically targetable drivers.

In this talk I will present our group’s work on the identification and validation of SIK2 as a key driver for spread of ovarian cancer cells to the abdominal cavity. Testing SIK2 as a therapeutic target in preclinical and early phase trials is currently planned. In addition, I will present our work on understanding the drivers of minimal residual disease through comprehensive genomic characterisation.